

Release date: 13 November 2018

STONEHAVEN INCUBATE CLOSSES INITIAL CAPITAL RAISING

Stonehaven Incubate has closed capital raising for its first investment, after securing the backing of a group of global life science and animal health investors.

Launched earlier this year as an innovative vehicle for human health companies to expand into the animal health sector, the funding will enable the company to invest directly in a number of early-stage opportunities, with potential for new company formation.

Stonehaven Incubate CEO, Dr Mark Heffernan, says the support of a sophisticated group of investors has provided the company with working capital and capital for seed investments. Stonehaven Incubate has already evaluated over 30 new opportunities for their potential to expand into animal health related products and technologies.

“Closing this first capital raising is an important milestone for the company, as we realise our vision of funding, developing and ultimately exiting start-up businesses,” says Dr Heffernan.

“We are actively working on progressing a number of exciting developments in the areas of therapeutics, digital and data, the microbiome, agriculture, diagnostics and nutrition.”

The company is currently investigating new opportunities around the globe, including Europe, the US and Australia.

“We anticipate that 2019 is going to be an exciting year for news for Stonehaven Incubate, based on the solid groundwork of opportunities we have been cultivating since formation earlier this year,” says Dr Heffernan.

Stonehaven Incubate is already a foundation shareholder in ANIZOME, a unique new company launched in May this year. ANIZOME offers the first commercial therapeutic microbiome discovery platform dedicated to animal health and nutrition, which bridges the gap between microbiome research and commercial development.

ends

Notes to editor:

Formed in February 2018, Stonehaven Incubate is headquartered in Switzerland. Its parent company, Stonehaven Holdings AG, was founded in 2015 by George Gunn, former CEO of Novartis AH.

For more information contact Mike Keeler at Garnett Keeler PR on +44 (0)20 8647 4467 or mike.keeler@garnettkeeler.com or visit www.stonehaven-incubate.com

STO/009/18